

Article

Not peer-reviewed version

Next-Generation Liver Surgery: Integrating Artificial Intelligence, Robotics, and Nanotechnology, A Narrative Review

[Fatemeh Amini](#)*

Posted Date: 27 January 2026

doi: 10.20944/preprints202601.1961.v1

Keywords: liver neoplasms; hepatectomy; robotic surgical procedures; artificial intelligence; nanotechnology; augmented reality; intraoperative complications; postoperative complications; treatment outcome; minimally invasive surgical procedures; imaging; three-dimensional; translational medical research



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a [Creative Commons CC BY 4.0 license](#), which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

Next-Generation Liver Surgery: Integrating Artificial Intelligence, Robotics, and Nanotechnology, A Narrative Review

Fatemeh Amini

West China School of Medicine, Sichuan University, Chengdu, China; amini2001fatemeh@gmail.com

Abstract

Liver resection offers the best chance of cure for hepatocellular carcinoma (HCC) and hepatic metastases, but complex anatomy, tumor variability, and risks such as bleeding and tissue deformation make it challenging. This narrative review explores how artificial intelligence (AI), robotics, and nanotechnology can be integrated across the surgical workflow from preoperative planning and intraoperative guidance to postoperative monitoring with a focus on hybrid systems (combinations of two or more technologies, like AI-guided robotic tools enhanced by nanotechnology) that may create meaningful synergies for better decision-making. Unlike most existing reviews, which examine single technologies in isolation or emphasize performance metrics without workflow context, we center the discussion on real surgeon challenges, translational readiness levels, adoption barriers, and situations where hybrids may not add value. Drawing on 2020–2026 evidence, we highlight the potential of AI for predictive insights, robotics for precision, and nanotechnology for targeted effects, while noting that most data come from small, retrospective, or preclinical studies with limited generalizability. This review addresses the growing gap between proposed hybrid innovations and their practical evaluation in clinical workflows. We outline a cautious, multidisciplinary roadmap for future validation, including ethical, regulatory, and equity considerations. It is aimed primarily at hepatobiliary surgeons and translational researchers interested in near to mid term adoption.

Keywords: liver neoplasms; hepatectomy; robotic surgical procedures; artificial intelligence; nanotechnology; augmented reality; intraoperative complications; postoperative complications; treatment outcome; minimally invasive surgical procedures; imaging; three-dimensional; translational medical research

Introduction

Liver resection remains a cornerstone for curative treatment of HCC and hepatic metastases, yet it is constrained by complex vascular anatomy, cirrhosis related risks, and the need for parenchyma preservation to avoid postoperative liver failure [2,4,18]. Traditional approaches often rely on preoperative imaging for planning and manual skill during execution, leading to variable outcomes. Reported recurrence and morbidity rates vary widely depending on tumor biology, cirrhosis severity, and institutional expertise, with recurrence rates up to 70% at 5 years in selected HCC series and morbidity in 20-40% of cases in retrospective series [3,8,17]. Emerging technologies AI for data integration, robotics for precise manipulation, and nanotechnology for targeted interventions offer a potential paradigm shift, but most literature examines them in silos, overlooking hybrid potential and translational gaps [1,10,13,50]. Unlike prior reviews that assess individual technologies, this review reframes liver surgery through a workflow centered hybrid systems lens, explicitly addressing when integration fails to add value. By synthesizing 2020-2026 evidence, we aim to provide a forward looking framework that advances surgical decision making without overhyping, distinguishing preclinical promise from clinical reality. Given the heterogeneity of technologies,

endpoints, and readiness levels, formal meta-analysis would be methodologically inappropriate and a systematic review framework would risk artificial homogeneity across fundamentally dissimilar technologies; instead, this narrative format maps what should be tested next, not what is already proven [11,52].




Figure 1. Conceptual framework of technology integration in liver surgery workflow.

Methods

This narrative review synthesizes clinical and preclinical evidence from 2020-2026 on AI, robotics, and nanotechnology in liver surgery, with a focus on hybrid integration. To ensure transparency and a priori specification of objectives, this narrative review was registered on PROSPERO (CRD420261289929). The registration included the planned inclusion criteria, search strategy, and objectives for evaluating hybrid systems in liver surgery.

Eligibility Criteria

Studies were included if they involved patients of any age or sex undergoing liver resection for primary or secondary hepatic malignancies, including HCC and liver metastases, using open or minimally invasive approaches. Eligible interventions encompassed AI for planning or guidance, robotic assisted surgery, nanotechnology for imaging or targeting, or hybrid combinations. Both randomized and nonrandomized designs were considered, with no language or date restrictions applied.

Searching and Screening

Both published and unpublished studies were sought. Main bibliographic databases searched included Embase (via Ovid), MEDLINE, PubMed, Science Citation Index (SCI), and Scopus. Google Scholar was used as a specialist database. No other methods for identifying studies were employed. A full search strategy is available in the PROSPERO protocol. Studies were screened independently by at least two reviewers (or person/machine combination), with a process to resolve differences.

Data Collection Process

Data were extracted independently by at least two reviewers (or person/machine combination), with a process to resolve differences. Authors were contacted for any required data not available in published reports. Risk of bias/study quality, reporting bias, and certainty of findings were not formally assessed, consistent with the narrative synthesis approach.

Planned Data Synthesis

No formal data synthesis was planned; data were described narratively without combination.

Current Review Stage

The review is ongoing, with formal searching, screening, and data extraction started but not completed.

Conceptual Role in Preoperative Planning

Preoperative planning in liver surgery involves tumor localization, vascular mapping, and functional liver volume estimation to minimize risks like ischemia or incomplete resection [12,14]. AI excels by integrating multimodal data (e.g., CT, MRI, omics) to predict recurrence and guide resectability, addressing surgeon challenges in high risk cirrhotic livers, though often in retrospective cohorts [2,6,7]. Machine learning models, for instance, combine radiomics with clinical variables to forecast early HCC recurrence post-resection with AUCs >0.80 in small pilot studies [3,16]. However, most models lack external validation and are susceptible to overfitting, limiting clinical generalizability [5,11]. Robotics contributes through virtual simulations, incorporating haptic feedback to rehearse complex resections like those in segment VIII, reducing planning uncertainty in feasibility trials [22,23,67]. Nanotechnology enhances imaging via targeted nanoparticles, such as glypican 3 conjugated agents, improving detection of microvascular invasion a key prognostic factor with up to 25% better tumor accumulation in preclinical models [33,35,41].

Conceptually, hybrid systems unify these: AI analyzes nano enhanced scans to create probabilistic maps, which robotic platforms simulate for rehearsal. This dynamic approach could account for patient-specific variability, potentially decreasing intraoperative adjustments and conversion rates, though current evidence is largely preclinical with limited external validity [34,59,61]. Hybrid value should be judged by cognitive offloading and workflow simplification, not technological sophistication alone, particularly in addressing margin uncertainty [15].

Intraoperative Guidance and Execution

Intraoperative challenges include achieving R0 margins, preserving vessels, and adapting to deformation in cirrhotic livers [13]. Robotics addresses these with tremor free precision and 3D visualization, showing lower blood loss (e.g., 200-300 mL) and conversion rates (4 -5%) in major hepatectomies for metastases (predominantly colorectal liver metastases, CRLM) compared to laparoscopy in meta analyses of predominantly retrospective data from high volume centers [9,19-21,23,25,27,28]. AI augments by overlaying navigation, segmenting tissues in real time, and predicting bleeding from vascular patterns in early feasibility studies [1,7]. Nanotechnology provides molecular tools, like fluorescence-guided nano probes for margin delineation or drug-eluting particles for targeted ablation, reducing off target effects in fibrotic tissue in preclinical settings [30,32,43].

Hybrid frameworks could enable adaptive resection: AI processes robotic sensor data and nano markers to adjust paths dynamically, as seen in AR-assisted robotic hepatectomies achieving sub centimeter precision and lower complications (10-30%) in small pilot cohorts [70,72,78]. This system supported approach may mitigate skill variability, particularly in minimally invasive HCC resections, but demands scrutiny for registration accuracy amid deformation, directly tackling bleeding risks and deformation mismatches [68,79,82].

Postoperative Monitoring and Outcomes

Postoperative focus includes complication detection, recovery optimization, and recurrence surveillance [18]. AI predicts morbidity using perioperative metrics, enabling early interventions for liver failure with accuracies >85% in retrospective analyses [6,8]. Robotics correlates with shorter

stays (5–7 days) and reduced morbidity in HCC cases due to minimal invasiveness in single center studies [9,26]. Nanotechnology supports via nano sensors for biomarker monitoring or sustained release systems for healing, showing 30-50% improved drug uptake in preclinical HCC models [42,45].

Hybrids could create feedback loops: AI interprets nano-delivered biomarkers from robotic-implanted devices to forecast recurrence, integrating with EHRs for personalized follow up. This may extend workflow impact, potentially informing recurrence free survival through earlier detection, though long-term data are sparse and from limited cohorts, solving real surveillance challenges without over interpreting pilot data [61,64].

Limitations, Safety Concerns, and Barriers to Adoption

AI risks dataset bias and overfitting, limiting generalizability across diverse populations in early studies [5,11]. Robotics incurs high costs (\$1-2 million/system) and steep learning curves, restricting access in low-resource settings [22,23,48,49]. Nanotechnology faces biocompatibility issues, with potential toxicity in cirrhotic livers in preclinical evaluations [29,37,38]. Hybrids compound these, requiring interdisciplinary validation; readiness varies AI/robotics in trials, nanotechnology preclinical [34,59,62]. Ethical concerns include data privacy, surgeon deskilling, and liability in AI-driven decisions [50,52,53]. Regulatory hurdles, like FDA approval, slow adoption, emphasizing need for honest discussion of neutral/negative trials; negative or neutral findings are likely underrepresented due to publication bias, particularly in early feasibility studies [5]. Additional barriers include lack of interoperability between proprietary platforms and risks of vendor lock-in. Without parallel investment in training and cost reduction, hybrid systems risk exacerbating disparities in global liver surgery [12,77].

Table 1. Nanotechnology Readiness Levels in Liver Surgery.

Nano Application	Evidence Level	Clinical Status
Fluorescence probes	Preclinical / early human pilots	Experimental
Drug-eluting particles	Preclinical	Not approved in US/EU
Targeted contrast agents	Animal models / phase I trials	Investigational
Nano-sensors for monitoring	Preclinical concepts	Not in clinical use

Evidence for Hybrid Systems

Evidence for hybrids is nascent, focusing on dual systems like AI-robotics for navigation or AI-nanotechnology for targeting, mostly in small, single-center studies [34,59,62]. AI-integrated robotics with AR adapts to deformation, supporting R0 resections in metastases without recurrence at 22 months in highly selected pilot patients, though with limited validity [70,71]. AI-nanotechnology optimizes HCC nanoparticle delivery, yielding 25% higher accumulation and lower toxicity in animal models [35,47]. Tri-hybrids (e.g., AI-guided robotic nano-probes) demonstrate 30-50% preclinical efficacy gains but lack clinical data; tri-hybrid systems currently remain conceptual or preclinical and should not be interpreted as near-term clinical solutions [31,54]. Key gaps: standardized interfaces, multicenter trials; barriers: overfitting, costs [11,77].

Table 2. Comparing Single-Technology vs. Hybrid Value in Liver Surgery.

Aspect	Single-Technology (e.g., AI Alone, Robotics Alone, Nano Alone)	Hybrid Systems (e.g., AI-Robotics-Nano Integration)
Strengths	Simpler implementation; lower cost; focused on specific pain points (e.g., AI for prediction, robotics for dexterity).	Potential synergies for adaptive workflows; addresses multiple challenges simultaneously (e.g., real-time margin adjustment).

Weaknesses	Limited scope; may not handle complexity like deformation or heterogeneity.	Increased complexity; higher risk of compounded errors; regulatory hurdles.
Evidence Maturity	Higher for AI/robotics (trials); lower for nano (preclinical).	Mostly preclinical/pilot; lacks RCTs.
Clinical Value	High for routine cases; reduces cognitive load in isolated tasks.	May add value in complex resections; could degrade performance in routine ones due to latency/setup.
Adoption Barriers	Cost/learning curve for robotics; bias for AI.	Vendor lock-in; interoperability issues; equity gaps.
When to Prefer	Standard procedures where one tech suffices.	High-risk cases needing multi-layered support, pending validation.

When Hybrid Systems May NOT Add Value

We intentionally include scenarios where hybrid systems may degrade performance, as these are underreported in current literature. While hybrids offer potential synergies, they may not always improve outcomes and could introduce drawbacks. Increased system complexity might lead to longer setup times or higher failure rates in resource-limited settings. Latency in real-time AI processing could delay critical decisions during bleeding events. Compounded failure modes, such as AI misinterpretation of nano data, risk amplifying errors. Regulatory burdens for hybrid approvals may outweigh benefits for routine cases, where single technologies suffice. We suggest tiered adoption: hybrids for complex cases, single tech for routine resections.

Current regulatory frameworks still place final accountability on the operating surgeon under current regulatory frameworks, underscoring the need for decision support not decision replacement AI, with acknowledgment of regulatory lag for hybrids.

Box 1: What Evidence Surgeons Should Demand Before Adoption

Before adopting hybrid systems in liver surgery, surgeons should demand robust, multicenter evidence addressing translational gaps. Key requirements include: (1) Prospective RCTs demonstrating workflow improvements (e.g., reduced operative time, margin positivity) over single technologies, with endpoints like intraoperative decision latency and conversion rates; (2) External validation of AI models to mitigate bias and overfitting, including diverse cohorts reflecting global populations; (3) Long term data on outcomes like recurrence free survival and morbidity, accounting for publication bias in neutral/negative trials; (4) Safety assessments, including failure mode analyses for compounded errors (e.g., AI latency during bleeding); (5) Cost effectiveness studies, factoring equity and interoperability to avoid vendor lock in; (6) Ethical evaluations, ensuring transparency, patient autonomy in consent, and surgeon accountability. Until such evidence exists, hybrids should be piloted in high volume centers with fallback protocols.

Future Roadmap

A phased, speculative roadmap, dependent on reimbursement models and regulatory harmonization, is proposed: (1) Short-term (1-3 years): Multicenter trials validating hybrids on workflow metrics (e.g., margin uncertainty reduction, intraoperative decision latency, conversion rates) in diverse cohorts. (2) Medium-term (3-5 years): Prototype development, like AI-robotics with nano-imaging, tested preclinically for safety. (3) Long-term (5+ years): RCTs on integrated systems, assessing cost-effectiveness and global equity. Gaps: Longitudinal hybrid impact studies, AI ethics. Multidisciplinary collaboration essential for potential standardization by 2030, though timelines remain uncertain.

Conclusions

Integrating AI, robotics, and nanotechnology could redefine liver surgery workflows, tackling surgeon challenges in HCC and hepatic metastases. Hybrids offer a pathway to enhanced decision making, but require rigorous validation to bridge hype and reality, particularly given evidence limitations. Surgeons should prioritize hybrids that demonstrably reduce uncertainty at decision critical moments, such as margin assessment or bleeding control, rather than those offering marginal technical enhancements. They should demand multicenter RCTs before adoption, remain cautious in routine cases where hybrids may add complexity without value, and advocate for equity focused implementations to avoid widening global disparities. Until such evidence exists, hybrid systems should be considered experimental adjuncts rather than standards of care.

References

1. Artificial Intelligence Applications in the Diagnosis, Treatment, and Prognosis of Hepatocellular Carcinoma - PMC - NIH. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12800664>
2. Artificial intelligence in hepatocellular carcinoma screening: applications and challenges. <https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1713887/full>
3. Machine learning integrating MRI and clinical features predicts early recurrence of hepatocellular carcinoma after resection | Scientific Reports - Nature. <https://www.nature.com/articles/s41598-026-36261-3>
4. Current status and prospects of artificial intelligence in liver cancer management. <https://www.sciencedirect.com/science/article/pii/S295026162500038X>
5. Study reveals AI strengths and limits in real-world liver cancer treatment - HAB Central. https://habcentral.habcommunity.com/article/study-reveals-ai-strengths-and-limits-in-real-world-liver-cancer-treatment?article_id=7066699&article_title=Study+reveals+AI+strengths+and+limits+in+real-world+liver+cancer+treatment
6. Can AI Guide the Decision to Transplant or Resect for Hepatocellular Carcinoma? | Gastroenterology and Hepatology | JAMA Network Open. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2839040>
7. Artificial Intelligence in Hepatocellular Carcinoma: Applications and | IJGM - Dove Medical Press. <https://www.dovepress.com/an-artificial-intelligence-pipeline-for-hepatocellular-carcinoma-from-peer-reviewed-fulltext-article-IJGM>
8. Artificial intelligence in predicting recurrence after first-line treatment of liver cancer: a systematic review and meta-analysis | BMC Medical Imaging. <https://link.springer.com/article/10.1186/s12880-024-01440-z>
9. Robotic liver resection for HCC reduced length of hospital stay, ICU admissions - Healio. <https://www.healio.com/news/gastroenterology/20221221/robotic-liver-resection-for-hcc-reduced-length-of-hospital-stay-icu-admissions>
10. Emerging Role of MRI-Based Artificial Intelligence in Individualized Treatment Strategies for Hepatocellular Carcinoma: A Narrative Review - NIH. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12706715>
11. Artificial Intelligence in Hepatopancreaticobiliary Surgery: A Systematic Review. <https://journal.hep.com.cn/artis/EN/10.20517/ais.2022.20>
12. The role of artificial intelligence and 3D printing in minimally invasive liver surgery. <https://www.oaepublish.com/articles/2574-1225.2024.78>
13. Artificial intelligence in the detection, characterisation and prediction of hepatocellular carcinoma: a narrative review - Translational Gastroenterology and Hepatology. <https://tgh.amegroups.org/article/view/6429/html>
14. Artificial Intelligence in Perioperative Planning and Management of Liver Resection | Request PDF - ResearchGate. https://www.researchgate.net/publication/377597661_Artificial_Intelligence_in_Periooperative_Planning_and_Management_of_Liver_Resection

15. Current state of artificial intelligence in liver transplantation - ScienceDirect.com. <https://www.sciencedirect.com/science/article/pii/S2451959625000034>
16. Machine learning integrating MRI and clinical features predicts early recurrence of hepatocellular carcinoma after resection - Nature. https://www.nature.com/articles/s41598-026-36261-3_reference.pdf
17. Role of artificial intelligence in the diagnosis and treatment of hepatocellular carcinoma. <https://www.wjgnet.com/2644-3236/full/v3/i4/96.htm>
18. Redefining precision medicine in hepatocellular carcinoma through omics, translational, and AI-based innovations. [https://www.jprecisionmedicine.org/article/S3050-6328\(25\)00003-4/fulltext](https://www.jprecisionmedicine.org/article/S3050-6328(25)00003-4/fulltext)
19. Robotic versus laparoscopic hepatectomy: meta-analysis of ... <https://pmc.ncbi.nlm.nih.gov/articles/PMC11957917>
20. An updated meta-analysis of the efficacy and safety of robot-assisted... https://journals.lww.com/md-journal/fulltext/2025/01030/an_updated_meta_analysis_of_the_efficacy_and.8.aspx
21. Robotic versus laparoscopic hepatectomy for liver malignancies ... [https://www.thelancet.com/journals/lanpe/article/PIIS2666-7762\(24\)00139-X/fulltext](https://www.thelancet.com/journals/lanpe/article/PIIS2666-7762(24)00139-X/fulltext)
22. Robotic Liver Resections: Current State-of-the-Art and Future ... <https://link.springer.com/article/10.1007/s40137-025-00469-5>
23. Laparoscopic versus Robotic Hepatectomy: A Systematic Review ... <https://www.mdpi.com/2077-0383/11/19/5831>
24. International experts consensus guidelines on robotic liver resection ... <https://pmc.ncbi.nlm.nih.gov/articles/PMC10494765>
25. Robotic versus conventional laparoscopic liver resections. <https://journals.sagepub.com/doi/10.1177/1457496920925637>
26. Robotic-assisted laparoscopic liver resection in hepatocellular ... <https://journal.hep.com.cn/hepatomaresearch/EN/10.20517/2394-5079.2020.86>
27. Robotic versus open resection for colorectal liver metastases in a ... [https://www.cell.com/heliyon/fulltext/S2405-8440\(24\)00831-4](https://www.cell.com/heliyon/fulltext/S2405-8440(24)00831-4)
28. Robotic versus laparoscopic liver resection: a systematic review and ... https://journals.lww.com/international-journal-of-surgery/fulltext/2025/08000/robotic_versus_laparoscopic_liver_resection__a.46.aspx
29. Advanced nanotheranostic approaches for hepatocellular carcinoma management. <https://www.sciencedirect.com/science/article/pii/S2949916X2500012X>
30. Application of nanotechnology in the treatment of hepatocellular carcinoma - Frontiers. <https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1438819/full>
31. Nanotechnology for the Diagnosis and Treatment of Liver Cancer - PMC - NIH. <https://pmc.ncbi.nlm.nih.gov/articles/PMC11681781>
32. Full article: Application of Nanotechnology in TACE Treatment of Liver Cancer. <https://www.tandfonline.com/doi/full/10.2147/IJN.S527518>
33. A Narrative Review on Functionalized Nanoparticles for the Treatment and Early Detection of Hepatocellular Carcinoma - MDPI. <https://www.mdpi.com/2076-3417/15/14/7649>
34. Convergence of nanotechnology and artificial intelligence in the fight against liver cancer: a comprehensive review | Discover Oncology | Springer Nature Link. <https://link.springer.com/article/10.1007/s12672-025-01821-y>
35. Recent advances in hepatocellular carcinoma-targeted nanoparticles - IOP Science. <https://iopscience.iop.org/article/10.1088/1748-605X/ad46d3/pdf>
36. Nanotechnology at the forefront of liver cancer diagnosis - ScienceDirect - DOI. <https://doi.org/10.1016/b978-0-443-13937-6.00004-4>
37. Advancements in nano drug delivery system for liver cancer therapy based on mitochondria-targeting - ScienceDirect. <https://www.sciencedirect.com/science/article/pii/S0753332224014069>
38. nanotechnology-driven therapeutics for liver cancer: clinical applications and pharmaceutical insights - ResearchGate. https://www.researchgate.net/publication/388876344_NANOTECHNOLOGY-

DRIVEN_THERAPEUTICS_FOR_LIVER_CANCER_CLINICAL_APPLICATIONS_AND_PHARMACEUTICAL_INSIGHTS

39. Nanoparticles and their application in the diagnosis of hepatocellular carcinoma. https://www.researchgate.net/publication/385657291_Nanoparticles_and_their_application_in_the_diagnosis_of_hepatocellular_carcinoma
40. Engineering nanotheranostic strategies for liver cancer - Baishideng Publishing Group. <https://www.wjgnet.com/1948-5204/full/v13/i10/1213.htm>
41. The improving strategies and applications of nanotechnology-based drugs in hepatocellular carcinoma treatment - Frontiers. <https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1272850/full>
42. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma - Theranostics. <https://www.thno.org/v11p5464.htm>
43. Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. <https://www.mdpi.com/1999-4923/14/1/41>
44. Engineered nanoparticles for imaging and targeted drug delivery in hepatocellular carcinoma | Experimental Hematology & Oncology - Springer Link. <https://link.springer.com/article/10.1186/s40164-025-00658-z>
45. Current advances in nanoparticle-based approaches for the hepatocellular carcinoma treatment - ScienceDirect. <https://www.sciencedirect.com/science/article/abs/pii/S2210740124002298>
46. Advances of Nanotechnology in the Diagnosis and Treatment of Hepatocellular Carcinoma. <https://www.semanticscholar.org/paper/Advances-of-Nanotechnology-in-the-Diagnosis-and-of-Escutia-Guti%C3%A9rez-Sandoval-Rodr%C3%ADguez/2774b8da70739a1ed08b337898cec1ab434a49af>
47. (PDF) Recent advances in hepatocellular carcinoma-targeted nanoparticles - ResearchGate. https://www.researchgate.net/publication/380312181_Recent_advances_in_hepatocellular_carcinoma-targeted_nanoparticles
48. Liver Robotic Surgery: A Review of Current Use and Future Perspectives - MDPI. <https://www.mdpi.com/2077-0383/14/19/7014>
49. Robotic Liver Resections: Current State-of-the-Art and Future Perspectives - Springer Link. <https://link.springer.com/article/10.1007/s40137-025-00469-5>
50. Review Article Artificial Intelligence and liver: Opportunities and barriers - ScienceDirect.com. <https://www.sciencedirect.com/science/article/pii/S1590865823009003>
51. Liver Robotic Surgery: A Review of Current Use and Future Perspectives - ResearchGate. https://www.researchgate.net/publication/396188100_Liver_Robotic_Surgery_A_Review_of_Current_Use_and_Future_Perspectives
52. The current status and future directions of artificial intelligence in the prediction, diagnosis, and treatment of liver diseases - Sage Journals. <https://journals.sagepub.com/doi/10.1177/20552076251325418>
53. The rise of robotics and AI-assisted surgery in modern healthcare - PMC - PubMed Central. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12181090>
54. Nano bio-robots: a new frontier in targeted therapeutic delivery. <https://www.frontiersin.org/journals/robotics-and-ai/articles/10.3389/frobt.2025.1639445/full>
55. The future of robotic liver surgery - Giulianotti. <https://hbsn.amegroups.org/article/view/39794/html>
56. A bright future for robotic surgery - Open MedScience. <https://openmedscience.com/bright-future-for-robotic-surgeons>
57. Robotic liver surgery: literature review and current evidence - OAE Publishing Inc. <https://www.oaepublish.com/articles/2574-1225.2020.90>
58. International experts consensus guidelines on robotic liver resection in 2023 - PMC. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10494765>
59. Convergence of nanotechnology and artificial intelligence in the fight against liver cancer: a comprehensive review | Discover Oncology | Springer Nature Link. <https://link.springer.com/article/10.1007/s12672-025-01821-y>

60. Total robotic liver transplant: the final frontier of minimally invasive surgery - ScienceDirect. <https://www.sciencedirect.com/science/article/pii/S1600613524002405>
61. Redefining precision medicine in hepatocellular carcinoma through omics, translational, and AI-based innovations. [https://www.jprecisionmedicine.org/article/S3050-6328\(25\)00003-4/fulltext](https://www.jprecisionmedicine.org/article/S3050-6328(25)00003-4/fulltext)
62. AI-Integrated Micro/Nanorobots for Biomedical Applications: Recent Advances in Design, Fabrication, and Functions - MDPI. <https://www.mdpi.com/2079-6374/15/12/793>
63. The future of robotic surgery | Stanford University School of Engineering. <https://engineering.stanford.edu/news/future-robotic-surgery>
64. Medical Micro/Nanorobots in Precision Medicine - Soto - The Advanced Portfolio - Wiley. <https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202002203>
65. Advancements and Challenges in Robotic Liver Transplantation - AZoRobotics. <https://www.azorobotics.com/News.aspx?newsID=15115>
66. World's First Remote Head & Neck Robotic Surgery | Yao Li | Borns Medical Robotics. <https://www.youtube.com/watch?v=kEZjp93p7OI>
67. Robotics as the natural evolution for minimally invasive surgery liver surgery: technological advances for patient and surgeon benefit - Digestive Medicine Research. <https://dmr.amegroups.org/article/view/7827/html>
68. Augmented and mixed reality in liver surgery: a comprehensive narrative review of novel clinical implications on cohort studies - PubMed Central. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12245099>
69. Robotic Liver Resections: Current State-of-the-Art and Future Perspectives - Springer Link. <https://link.springer.com/article/10.1007/s40137-025-00469-5>
70. Augmented Reality and Image-Guided Robotic Liver Surgery - MDPI. <https://www.mdpi.com/2072-6694/13/24/6268>
71. Robotic Liver Resections: Current State-of-the-Art and Future Perspectives - ResearchGate. https://www.researchgate.net/publication/396198790_Robotic_Liver_Resections_Current_State-of-the-Art_and_Future_Perspectives
72. Leveraging augmented reality for dynamic guidance in 3-dimensional laparoscopic and robotic liver surgery: a prospective case series study. <https://astr.or.kr/DOIx.php?id=10.4174%2Fastr.2025.109.1.44>
73. Augmented Reality and Navigation Technologies in Liver Surgery | Nature Research Intelligence. <https://www.nature.com/research-intelligence/nri-topic-summaries/augmented-reality-and-navigation-technologies-in-liver-surgery-micro-1206576>
74. The role of 3D printing, virtual and augmented reality in liver surgery: The technological imperative! | Gastroenterology and Functional Medicine. <https://www.hksmp.com/journals/gfm/article/view/383>
75. Application value of mixed reality in hepatectomy for hepatocellular carcinoma. <https://www.wjgnet.com/1948-9366/full/v14/i1/36.htm>
76. Enhancing liver surgery and transplantation: the role of 3D printing and virtual reality. <https://journal.hep.com.cn/artis/EN/10.20517/ais.2024.07>
77. Cost-effectiveness and clinical impact of robotic-assisted hepatectomy - PubMed Central. <https://pmc.ncbi.nlm.nih.gov/articles/PMC11997018>
78. The value of Augmented Reality in surgery — A usability study on laparoscopic liver surgery. <https://www.sciencedirect.com/science/article/pii/S1361841523002037>
79. (PDF) Integrating Mixed Reality, Augmented Reality, and Artificial Intelligence in Complex Liver Surgeries: Enhancing Precision, Safety, and Outcomes - ResearchGate. https://www.researchgate.net/publication/391830083_Integrating_Mixed_Reality_Augmented_Reality_and_Artificial_Intelligence_in_Complex_Liver_Surgeries_Enhancing_Precision_Safety_and_Outcomes
80. Augmented reality in hepatobiliary-pancreatic surgery: a technology at your fingertips | Cirugía Española (English Edition) - Elsevier. <https://www.elsevier.es/en-revista-cirugia-espanola-english-edition--436-articulo-augmented-reality-in-hepatobiliary-pancreatic-surgery-S2173507723000388>
81. Augmented reality in liver surgery - HAL-Inria. <https://inria.hal.science/hal-04414274/document>
82. Augmented reality during laparoscopic liver resection: a work in progress that is terribly necessary - Laurent. <https://ls.amegroups.org/article/view/4686/html>

83. Advanced liver surgery training in collaborative VR environments | Computers and Graphics. <https://dl.acm.org/doi/10.1016/j.cag.2024.01.006>
84. Augmented Reality Integration for Surgical Enhancement in Hepatic Surgery - Review of the Current Literature - PubMed. <https://pubmed.ncbi.nlm.nih.gov/41196075>
85. Enhancing liver surgery and transplantation: the role of 3D printing and virtual reality. <https://www.oaepublish.com/articles/ais.2024.07>

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.